Charles Schwab Investment Management Inc. Increases Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Charles Schwab Investment Management Inc. boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 17.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,274,003 shares of the company's stock after purchasing an additional 333,323 shares during the period. Charles Schwab Investment Management Inc. owned about 0.58% of Recursion Pharmaceuticals worth $15,372,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $26,000. Private Trust Co. NA purchased a new stake in Recursion Pharmaceuticals during the fourth quarter valued at $27,000. GAMMA Investing LLC lifted its holdings in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after acquiring an additional 4,948 shares during the period. KBC Group NV boosted its position in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after purchasing an additional 3,377 shares during the last quarter. Finally, Colonial River Investments LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $68,000. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Price Performance

Recursion Pharmaceuticals stock traded up $0.11 during midday trading on Monday, reaching $6.79. 15,938,292 shares of the stock traded hands, compared to its average volume of 10,548,929. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12 month low of $5.60 and a 12 month high of $12.36. The stock's fifty day moving average is $7.47 and its 200-day moving average is $7.01. The stock has a market cap of $2.73 billion, a P/E ratio of -4.44 and a beta of 0.85.

Remove Ads

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the prior year, the firm posted ($0.42) EPS. The company's revenue for the quarter was down 57.8% on a year-over-year basis. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. Leerink Partners reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of "Hold" and an average target price of $8.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.